# Intermittent Selumetinib for Uveal Melanoma

> **NCT02768766** · PHASE1 · COMPLETED · sponsor: **Shaheer A. Khan** · enrollment: 42 (actual)

## Conditions studied

- Uveal Melanoma

## Interventions

- **DRUG:** Selumetinib, 100mg
- **DRUG:** Selumetinib, 125mg
- **DRUG:** Selumetinib, 150mg
- **DRUG:** Selumetinib, 175mg
- **DRUG:** Selumetinib, 200mg
- **DRUG:** Selumetinib, 225mg

## Key facts

- **NCT ID:** NCT02768766
- **Lead sponsor:** Shaheer A. Khan
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-28
- **Primary completion:** 2020-09-18
- **Final completion:** 2020-09-18
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2023-08-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02768766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02768766, "Intermittent Selumetinib for Uveal Melanoma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02768766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*